August 12, 2019 8:32am

The sector, “our universe has taken sudden and sharp turns in multiple weeks, investors are again and again rattled … questioning their cell and gene therapy allocations.”

As I had said on Friday, “Many say, don’t touch your allocation – I say just the opposites – WEED out some not all!  Goals change as do many sector equities’ horizon after the last weeks and months; your portfolio should change along with them.”

From a positive view, pick-up stocks might be an alternative “game” for traders – some are ripe!

Framing the week’s headlines, geo-political monetary disruptions, volatility as earnings “whine”down!


The remainder of the month’s trading sessions will be critical for the RegMed sector which will establish whether expectation of August and quarter’s (Q2) reporting initiate tumultuous value propositions. 


Dow futures are DOWN -60% (-157 points), S&P futures are DOWN -0.60% (-18 points) and NASDAQ futures are also DOWN -0.68% (-52 points)


U.S. stock index futures have dropped and are fluctuating, pressured by worries that an ongoing trade dispute between Washington and Beijing could tip the world and U.S. economies into recession;

European stocks reverse early gains as the pan-European Stoxx 600 slipped back to the flat line by mid-morning after gaining almost 1% in early trade;

Asia Pacific traded mixed, following a volatile week for global markets as growing trade war fears dented investor sentiment; markets in Japan, India and Singapore are closed for public holidays. While all eyes continue to be on the yuan as the People’s Bank of China set the official midpoint reference for the yuan at 7.0211 per dollar — weaker than Friday’s session…

Data docket: the federal budget for July is expected to be published at around 2 p.m. ET.



Trade rules the headlines … not clinical data or acquisitions and certainly wasn’t earnings!

The US designated China as a currency manipulator following the yuan’s move below 7 against the dollar as a weaker currency makes a country’s exports cheaper and President Trump’s administration has consistently complained that a cheaper yuan would give China a trade advantage.

I am a "bit" under-the-weather this a.m. ... probably didn't drink enough (1 drink) over the weekend!


From Friday’s evening post, “after the sessions and week’s numbers, there’s still a directional signal for the new periods coming. Pre-open indications: as I had stated, be ready for some of the upside to be depreciated by profit taking and many answered the call. The real question is what are the BUY catalysts, just being oversold for trader’s play or true investor reactions?

•             The NASDAQ was down -80.02 or -1% to 7,959.14;

•             The IBB closed down -0.38% while the XBI closed down -0.91%;

•             The close was negative with an A/D Line of 11/30 and 2 flats and 2 acquired;

•             Friday’s range of the 11 upside was +0.06% (FIXX) to +3.93% (ONVO) while the 11 downside ranged from -0.17% (NTLA) to -1`0.15% (BCLI);

•             3 out of the 11 upside had higher than the 3 month average volume;

•             11 out of the 30 downside had higher than the 3 month average volume;

August has 3 POSITIVE and 4 NEGATIVE closes, so far


Changes in the spectrum of I-Bank coverage:  JMP Securities, a San Francisco based investment bank, announced that it hired Reni Benjamin, Ph.D. as managing director and equity research analyst covering biotechnology.  A good man and a good friend... could have needed a “weather change” (? or!)


Companies in my headlights – It’s your decision; I provide an idea and context:

*** I am NOT straying from my position – let ‘em roll *** Note: we are in the biggest CASINO in the world!


Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.